[Ipilimumab and metastatic lung cancer: Can we change the natural history of the disease?].
BACKGROUND
Ipilimumab (anti CTLA-4 antibody) aims to activate antitumor immunity. This treatment is being evaluated in non-small cell lung cancer.


METHODS
We report a case of a stage IV adenocarcinoma patient randomized in 2008 in the phase II trial CA 184-104 evaluating the combination of ipilimumab to chemotherapy with carboplatin and paclitaxel. After an initial partial response to chemotherapy, the patient achieved a complete response with ipilimumab as maintenance therapy. However, it was complicated by grade 3 gastro-intestinal toxicity leading to stop the ipilimumab. However, this complete response persists after 6 years.


CONCLUSIONS
Our case illustrates the contribution of immunotherapy at least in some patients. The mechanisms of action, relationship between efficacy and toxicity and predictors of efficacy remain to be defined.
Service d'oncologie multidisciplinaire et innovations thérapeutiques, Aix-Marseille université, Assistance publique-Hôpitaux de Marseille, 13915 Marseille cedex 20, France.
A
A
Boyer
Service d'oncologie multidisciplinaire et innovations thérapeutiques, Aix-Marseille université, Assistance publique-Hôpitaux de Marseille, 13915 Marseille cedex 20, France; Inserm U911, centre de recherche en oncologie biologique et oncopharmacologie, faculté de médecine, Aix-Marseille université, 13385 Marseille cedex 05, France.
L
L
Greillier
Service d'oncologie multidisciplinaire et innovations thérapeutiques, Aix-Marseille université, Assistance publique-Hôpitaux de Marseille, 13915 Marseille cedex 20, France.
H
H
Barazzutti
Service d'oncologie multidisciplinaire et innovations thérapeutiques, Aix-Marseille université, Assistance publique-Hôpitaux de Marseille, 13915 Marseille cedex 20, France; Inserm U911, centre de recherche en oncologie biologique et oncopharmacologie, faculté de médecine, Aix-Marseille université, 13385 Marseille cedex 05, France.
P
P
Tomasini
Service d'oncologie multidisciplinaire et innovations thérapeutiques, Aix-Marseille université, Assistance publique-Hôpitaux de Marseille, 13915 Marseille cedex 20, France; Inserm U911, centre de recherche en oncologie biologique et oncopharmacologie, faculté de médecine, Aix-Marseille université, 13385 Marseille cedex 05, France. Electronic address: fabrice.barlesi@ap-hm.fr.
F
F
Barlesi
D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D017322:Clinical Trials, Phase II as Topic; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D000074324:Ipilimumab; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D012074:Remission Induction; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D000074324:Ipilimumab; D016190:Carboplatin; D017239:Paclitaxel
Adénocarcinome bronchique; Bronchial adenocarcinoma; Immunotherapy; Immunothérapie; Ipilimumab; Remission induction; Rémission